ATE203402T1 - Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz - Google Patents

Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz

Info

Publication number
ATE203402T1
ATE203402T1 AT92107421T AT92107421T ATE203402T1 AT E203402 T1 ATE203402 T1 AT E203402T1 AT 92107421 T AT92107421 T AT 92107421T AT 92107421 T AT92107421 T AT 92107421T AT E203402 T1 ATE203402 T1 AT E203402T1
Authority
AT
Austria
Prior art keywords
dementia
dimethylphenyl
pyrrolidinyl
acetamide
oxo
Prior art date
Application number
AT92107421T
Other languages
English (en)
Inventor
Eiichi Otomo
Yoshiyuki Takasu
Tadashi Shiotani
Kazuo Hasegawa
Akira Honma
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of ATE203402T1 publication Critical patent/ATE203402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT92107421T 1991-05-02 1992-04-30 Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz ATE203402T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22981891 1991-05-02
JP22981991 1991-05-02

Publications (1)

Publication Number Publication Date
ATE203402T1 true ATE203402T1 (de) 2001-08-15

Family

ID=26529012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92107421T ATE203402T1 (de) 1991-05-02 1992-04-30 Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz

Country Status (21)

Country Link
US (1) US5886023A (de)
EP (1) EP0515866B1 (de)
KR (1) KR100310590B1 (de)
AT (1) ATE203402T1 (de)
AU (2) AU1595492A (de)
CA (1) CA2067614C (de)
CZ (1) CZ281170B6 (de)
DE (1) DE69231955T2 (de)
DK (1) DK0515866T3 (de)
ES (1) ES2160097T3 (de)
GR (1) GR3036970T3 (de)
HU (1) HU224689B1 (de)
IE (1) IE921377A1 (de)
IL (1) IL101738A (de)
MX (1) MX9202058A (de)
NO (1) NO312813B1 (de)
PT (1) PT515866E (de)
RU (1) RU2070042C1 (de)
SG (1) SG49650A1 (de)
SK (1) SK279285B6 (de)
TW (1) TW199096B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000048847A (ko) * 1996-10-01 2000-07-25 스즈키 다다시 미토콘드리아 막 안정화제
DE69823851D1 (de) 1997-07-15 2004-06-17 Daiichi Seiyaku Co Nefiracetam zur prophylaxe und behandlung von propofol verursachtem gedächtnisschwund
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
HK1048268A1 (zh) * 1999-05-31 2003-03-28 第一制药株式会社 神经元死亡抑制剂
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6423739B1 (en) 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
EP1356812B1 (de) * 2000-12-28 2009-05-13 Hamilton Pharmaceuticals, Inc. Arzneimittel zur behandlung und vermeidung neurogener schmerzen
JP2005501108A (ja) * 2001-08-22 2005-01-13 第一製薬株式会社 神経変性治療におけるネフィラセタムの使用
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
RU2327480C1 (ru) * 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
ES2865504T3 (es) * 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
AU2011215870B2 (en) * 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
IT1141287B (it) * 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
US4385053A (en) * 1981-03-11 1983-05-24 Barry Reisberg Treatment for human memory impairment associated with aging
JPH0699307B2 (ja) * 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti

Also Published As

Publication number Publication date
HUT62790A (en) 1993-06-28
KR920021143A (ko) 1992-12-18
DK0515866T3 (da) 2001-09-24
AU1595492A (en) 1992-11-05
MX9202058A (es) 1993-03-01
IE921377A1 (en) 1992-11-04
NO921724L (no) 1992-11-03
DE69231955T2 (de) 2002-04-04
RU2070042C1 (ru) 1996-12-10
EP0515866A1 (de) 1992-12-02
DE69231955D1 (de) 2001-08-30
NO312813B1 (no) 2002-07-08
HU9201477D0 (en) 1992-07-28
ES2160097T3 (es) 2001-11-01
TW199096B (de) 1993-02-01
CZ281170B6 (cs) 1996-07-17
IL101738A (en) 1999-01-26
SK279285B6 (sk) 1998-09-09
KR100310590B1 (ko) 2001-12-28
HK1002153A1 (en) 1998-07-31
CA2067614A1 (en) 1992-11-03
US5886023A (en) 1999-03-23
IL101738A0 (en) 1992-12-30
PT515866E (pt) 2001-11-30
EP0515866B1 (de) 2001-07-25
GR3036970T3 (en) 2002-01-31
AU697936B2 (en) 1998-10-22
CS130692A3 (en) 1992-11-18
SG49650A1 (en) 1998-06-15
HU224689B1 (hu) 2005-12-28
NO921724D0 (no) 1992-04-30
CA2067614C (en) 2002-07-30
AU3774595A (en) 1996-03-07

Similar Documents

Publication Publication Date Title
ATE203402T1 (de) Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69310065D1 (de) Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose
DE69422450D1 (de) Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
DE69232323D1 (de) Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
DE69324859D1 (de) Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis
DE602004027171D1 (de) Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
FI101849B1 (fi) Antimikrobiset koostumukset ja niiden käyttö silmälääkkeiden säilömiseksi ja piilolinssien hoitamiseksi
NO921525L (no) L-alfa-glyserofosforyl-d-myo-inositol for behandling av perifere nervelidelser og hjernelidelser
DE69424747D1 (de) Pharmazeutische Zusammensetzung zur Vorbeugung oder Behandlung von Knochenbrüchen
DE69326188D1 (de) Verwendung von N-Acylderivaten von Aminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von neurogenen endoneuralen Ödemen der peripheren Nerven
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
DK0826373T3 (da) Forebyggende middel mod postoperativ astigmatisme
DE69325512D1 (de) Verwendung von remacemid zur behandlung des morbus parkinson
ATE115857T1 (de) Verwendung von benzimidazolin-2-oxo-1- carbonsäurederivaten bei der behandlung organischer gehirnerkrankungen.
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
ATA162693A (de) Mittel zur behandlung und pflege von hufen
ATE96039T1 (de) Arzneimittel und ihre verwendung zur behandlung von parasitosen.
DE68907433D1 (de) Verwendung von dimetylheptylphenylbutanoylethanolamin bei der behandlung von hyperuricemie.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee